Want to join the conversation?
Boston, Massachusetts-based $VRTX said that it expects to increase the number of people eligible for Kalydeco and Orkambi drugs in 2016 through label expansion efforts. $VRTX added that it is awaiting for US FDA's approval of cystic fibrosis drug Kalydeco in people with CF ages 2 and older who have certain residual function mutations.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.